Platelet activation in response to dual stimulation with collagen and thrombin results in the formation of a subpopulation of activated platelets known as coated platelets. Coated platelets are characterized by high surface levels of alpha granule proteins and phosphatidylserine, which support the assembly of procoagulant protein complexes.
Introduction
The process of platelet activation involves several distinct signaling events that induce shape change, granule release, aggregation, and rearrangement of membrane phospholipids. 1 Under physiological conditions, these signaling events can be initiated by multiple agonists acting synchronously or synergistically to generate distinct populations of activated platelets. The heterogeneous nature of activated platelets has been demonstrated in several recent studies in which biochemical, morphological, or physiological differences were observed among subpopulations of platelets activated by strong agonists such as collagen or thrombin. [2] [3] [4] [5] A unique subpopulation of activated platelets, characterized by the surface retention of large amounts of the alpha granule proteins fibrinogen, factor V, thrombospondin, and von Willebrand factor (VWF), has been described recently by Dale and colleagues. 2, 6 In addition to retaining high levels of alpha granule proteins on their surface, these activated platelets express surface phosphatidylserine and are able to support the assembly of the prothrombinase complex 2 and other procoagulant proteins. 3, 6, 7 Because this subpopulation of activated platelets was initially observed after the dual stimulation of human platelets with collagen and thrombin, they were called COAT-platelets (an acronym for collagen and thrombin activated platelets). 2 It is now known, however, that a similar subpopulation of activated platelets can be generated by other strong agonists or combinations of agonists. 6, 8 For this reason, the term "coated platelets" has been proposed to refer to the subpopulation of activated platelets that are coated with high levels of procoagulant proteins. 9 For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From 
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During the formation of coated platelets, alpha granule proteins are covalently modified with serotonin by a transglutaminase. These serotonin-derivatized alpha granule proteins are then retained on the surface of the activated platelet through interactions with multiple low-affinity serotonin binding sites. 6, 10 The transglutaminase responsible for conjugating serotonin to alpha granule proteins has not been identified, but factor XIIIA has been suggested as a possible candidate. 6 Platelets contain high levels of factor XIIIA 11 and generation of coated platelets in response to stimulation with thrombin and convulxin (a specific agonist for the platelet collagen receptor, GPVI) can be inhibited by an inactivating anti-factor XIII antibody. 6 Platelets also contain other transglutaminases, however, and the exact role of factor XIIIA in the formation of coated platelets is unknown.
The physiological function of coated platelets is not well defined, but the high levels of procoagulant proteins on their surface suggest that they may provide sites for rapid thrombin generation. Initial studies of human platelets stimulated with varying concentrations of collagen and thrombin showed a close correlation between coated platelet formation and prothrombinase activity. 2 More recently, the rate and amplitude of thrombin generation were found to correlate directly with coated platelet formation in an in vitro model of coagulation utilizing monocyte tissue factor as the initiating stimulus. 3 Very little is known, however, about the formation or function of coated platelets in mice or other experimental animals.
In this study, we demonstrate that coated platelets are formed efficiently when murine platelets are stimulated with thrombin and convulxin. Using mice deficient in FcR , we test the hypothesis that formation of coated platelets requires an intact
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From GPVI/FcR signaling pathway. Finally, using factor XIIIA-deficient mice, we test the hypothesis that the factor XIII transglutaminase is necessary for formation of coated platelets.
Materials and methods

Reagents, antibodies, and mice
Purified bovine prothrombin, factor Va, factor Xa and -thrombin were obtained C mplete protease inhibitor, EDTA free was obtained from Roche Diagnostics (Mannheim, Germany) C57BL/6 mice and FcR null mice 12 on the C57BL/6 genetic background were obtained from The Jackson Laboratory (Bar Harbor, ME). FXIIIA (-/-) mice 13 were crossed with C57BL/6 mice for a single generation and then backcrossed with FXIIIA (-/-) mice to generate heterozygous (FXIIIA (+/-)) and homozygous (FXIIIA (-/-)) littermates for study. Plasma factor XIII activity was measured using the Pefakit Factor
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 6 XIII (Pentapharm Ltd, Basel). All mice were housed in pathogen-free conditions at the University of Iowa Animal Care Facility under NIH guidelines and approved animal care protocols.
Platelet isolation
Whole blood was obtained by cardiac puncture and washed platelets were isolated as described previously.
14 Washed platelets were resuspended in modified Tyrode's buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na 2 HPO 4 , 12 mM NaHCO3, 20 mM HEPES, 1 mM MgCl 2 , 5 mM glucose, 0.05% (w/v) fatty acid-free bovine serum albumin, pH 7.35), and platelet concentration was evaluated using a HemaVet cell counter (ABC Technologies).
Flow cytometry
Washed platelets were suspended in Tyrode's buffer containing 2.0 mM CaCl 2 at a concentration of 1 x 10 7 /ml. Platelets were either left unstimulated or stimulated with convulxin (250 ng/mL), thrombin (0.5 U/mL), convulxin plus thrombin, or ionomycin (3 µM) plus thrombin for the indicated times at 37°C without stirring. Platelets were then incubated with the appropriate antibody for two minutes unless otherwise indicated.
Following this incubation period the platelets were immediately fixed in 1% 
Platelet procoagulant activity
Platelet procoagulant activity was measured in a modified prothrombinase assay.
14 Reactions were performed in polypropylene 96 well microplates at 37°C.
Washed platelets (3 X 10 6 /well) were either left unstimulated or stimulated with convulxin (250 ng/mL), thrombin (0.5 U/mL), or thrombin plus convulxin at 37°C in modified Tyrodes buffer containing 2.9 mM CaCl 2 and 0.05% (w/v) fatty acid-free bovine serum albumin. After five minutes, factor Xa (3 nM) and factor Va (6 nM) were added, followed one minute later by prothrombin (4 µM). At three minutes, a subsample of the reaction mixture was transferred into Tris-EDTA cuvette buffer (0.05M Tris-HCl, 120 mM NaCl, 2.0 mM EDTA, 0.05% bovine serum albumin, pH 7.5). Thrombin activity was measured chromogenically using the substrate S-2238 (3 mM) in a Spectramax 190 microplate spectrophotometer (Molecular Devices, Sunnyvale CA).
Cellular transglutaminase activity
Platelet lysates were prepared by adding an equal volume of 2X cell lysis buffer (2% Triton X-100, 100 mM Tris pH 7.3 with Complete protease inhibitor, EDTA free) to washed platelets resuspended in Tyrodes. Transglutaminase activity was determined
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 8 using a colorimetric microassay (TG-Covtest; Covalab, Lyon, France) per the manufacturer's recommendations. The TG-Covtest measures the transglutaminasemediated covalent coupling of biotinylated cadaverine to carbobenzoxy (CBZ) -Gln-Gly coated plates. Platelet lysates were incubated in CBZ-Gln-Gly coated wells in the presence of calcium, the reducing agent dithiothreitol, and biotinylated cadaverine. In the presence of active transglutaminase biotinylated cadaverine will be covalently lined to the glutaminyl residue of the CBZ-Gln-Gly peptide. Streptavidin-labeled peroxidase is then added, and peroxidase activity is evaluated using a chromogenic substrate. Activity is reported as mU/mg of platelet protein lysates using the supplied guinea pig transglutaminase as the reference standard.
Statistical analysis
The unpaired, 2-tailed Student t test was used to compare values between C57BL/6 and FcR (-/-), between FXIIIA (+/-) and FXIIIA (-/-) mice, and in comparisons of cellular transglutaminase activity between FXIIIA and C57BL/6 mice. A value of P < 0.05 was used to define statistical significance. Values are reported as mean ± SE.
Results
Formation of murine coated platelets
Platelets isolated from C57BL/6 mice were either left unstimulated or stimulated with convulxin, thrombin, or convulxin plus thrombin. Two subpopulations of activated platelets with different levels of fibrinogen surface retention were observed. The first For personal use only. on October 3, 2017. by guest www.bloodjournal.org From subpopulation (indicated by region M1 in Figure 1A ), observed after stimulation with a single agonist (either convulxin or thrombin), had modestly increased amounts of surface fibrinogen relative to the unstimulated platelet population. The second subpopulation of activated platelets (indicated by region M2 in Figure 1A ), which represented a minor fraction of the platelets following stimulation with thrombin and the predominant fraction after dual stimulation with convulxin plus thrombin, was characterized by a higher level of surface retained fibrinogen. This second group of activated platelets, which corresponds to the human coated platelet described by Dale et al, 6 represented approximately 70% of the platelet population after dual stimulation by convulxin plus thrombin.
When the surface retention of another secreted alpha granule protein, VWF, was examined, a similar pattern was observed. Intermediate levels of surface VWF retention occurred when platelets were activated by a single agonist, such as thrombin (indicated by region M1 in Figure 1B ), and high levels of surface VWF were seen after dual stimulation with convulxin plus thrombin (indicated by region M2 in Figure 1B ). These observations demonstrate that murine platelets form a subpopulation of activated platelets with high surface levels of alpha granule proteins similar to coated platelets observed in humans.
We next evaluated fibrinogen receptor activation utilizing a recently described monoclonal antibody (PE-JON/A) that specifically recognizes the active form of murine Figure 3A ) and increased binding of PE-JON/A (indicated by region M1 in Figure 3B ). After three minutes, the majority of platelets stimulated with convulxin plus thrombin began to acquire characteristics of the coated platelet with high levels of surface fibrinogen (indicated by region M2 in Figure 3A 
convulxin and thrombin regardless of whether PE-JON/A was added before (54 ± 2%) or after (69 ± 4%) agonist addition. In both thrombin and convulxin/thrombin stimulated platelets the addition of two to six-fold greater concentrations of PE-JON/A had no additional effects on fibrinogen retention. These results indicate that the timing of PE-JON/A addition in relationship to platelet activation has minimal or no effect on the degree of fibrinogen binding to either activated or coated platelets. To determine if the defect in coated platelet formation in FcR (-/-) platelets is associated with a decrease in platelet procoagulant activity, platelet-dependent thrombin generation was measured in a prothrombinase assay. Using wild type platelets, thrombin generation was amplified five-fold following dual stimulation with convulxin plus thrombin ( Figure 5A ). Platelet activation with convulxin or thrombin alone resulted in only a slight (1.5 to 2 fold) increase in prothrombinase activity ( Figure 5A ). When the platelet prothrombinase assay was performed using platelets obtained from FcR (-/-) mice, no significant increase was seen with convulxin alone, and no amplification of platelet prothrombinase activity was observed following dual agonist activation with convulxin plus thrombin. Factor XIIIA has been proposed to be the transglutaminase responsible for the formation of coated platelets. 6 To determine the role of platelet factor XIIIA in coated platelet formation, we measured P-selectin exposure, annexin V binding and coated One plausible explanation for the lack of influence of factor XIII deficiency on coated platelet formation is that other platelet transglutaminases may compensate for the lack of FXIIIA. To examine this possibility, total cellular transglutaminase activity was 
Role of FcR in coated platelet formation
Discussion
This study demonstrates that coated platelet formation occurs following stimulation of murine platelets with two strong agonists, convulxin and thrombin.
Characteristic features of the murine coated platelet include high surface retention of alpha granule proteins, such as fibrinogen and VWF, decreased binding of a monoclonal antibody specific for the activated form of IIb 3, and high level exposure of platelet phosphatidylserine. These features are very similar to those seen in human coated platelets. 2, 6 In mice, however, coated platelets appear to form more readily than in humans because up to 70% of wild type murine platelets became coated after stimulation by convulxin and thrombin compared with 30-50% of human platelets stimulated with the same agonists. 2, 3 The other main finding from our study is that FcR , but not factor XIIIA, is necessary for formation of murine coated platelets in response to convulxin and thrombin.
A common characteristic of murine and human coated platelets is the decreased recognition of activated IIb 3 by a monoclonal antibody specific for the activated form of IIb 3. This phenomenon of paradoxically decreased recognition of activated IIb 3
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coated platelets has been demonstrated with the PAC-1 antibody in studies with human platelets. 6 Because fibrinogen and PAC-1 compete for occupancy of an identical binding site on IIb 3, the decreased binding of PAC-1 to IIb 3 on the human coated platelet surface has been proposed to be due to an increased affinity of fibrinogen for the activated IIb 3 receptor on the surface of the coated platelet relative to PAC-1.
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Unlike PAC-1, however, JON/A, recognizes an IIb 3 epitope outside of the fibrinogenbinding site and does not compete with fibrinogen for binding of the activated IIb 3 receptor. 15 . In agreement with these findings we found that both FITC and PE labeled JON/A bind to "activated" but not "coated" platelets ( Figure 2 ). These results suggest that a different mechanism other than competition for the fibrinogen binding site is 
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These results are in concordance with a model in which tyrosine kinase signaling, triggered by GPVI, is the primary mediator of intracellular signaling by collagen. 1 Thrombin, unlike collagen, primarily interacts with receptors known to signal through G protein regulated pathways, which suggests that interaction of these two differentially regulated second messenger pathways may be required for maximal coated platelet formation. Interestingly, coated platelet formation occurred normally in FcR (-/-) platelets stimulated with ionomycin plus thrombin, which indicates that ionomycin, a calcium ionophore, can bypass the need for signaling through GPVI/FcR .
Previous studies using small molecule transglutaminase inhibitors suggested that a platelet-derived transglutaminase is necessary for coated platelet formation. 6 Because monoclonal antibodies to factor XIII were observed to inhibit coated platelet formation, factor XIIIA was proposed as the responsible transglutaminase. 6 Up to 50% of the total factor XIII activity in blood is contained within platelets, 11 and factor XIIIA has been implicated in the generation of platelet procoagulant activity after adherence to collagen under flow conditions. 4 FXIIIA or a closely related transglutaminase has also recently been demonstrated to play an important role in the activation of platelet alpha granule secretion, 17 and in the enhancement of monocyte activation in atherosclerosis through covalent homodimerization of the angiotensin II receptor. 18 Given the proposed important roles of factor XIIIA in these multiple intracellular and extracellular platelet processes, we examined the effect of factor XIIIA deficiency on coated platelet formation in FXIIIA (-/-) mice. FXIIIA (-/-) mice had previously been demonstrated to have a bleeding diathesis similar to that seen in factor XIII deficient humans, including a high incidence of spontaneous hemorrhage and intrauterine
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From pregnancy loss. 13, 19 Surprisingly, we found that complete absence of factor XIII activity did not affect coated platelet formation, exposure of procoagulant phospholipids, or full expression of P-selectin in murine platelets. These findings indicate that the factor XIII transglutaminase is not necessary for coated platelet formation, and suggest that another cellular transglutaminase may compensate for the absence of factor XIIIA. Consistent with this possibility, platelet lysates obtained from FXIIIA (-/-) mice did not have decreased levels of total transglutaminase activity relative to C57BL/6 mice.
Tissue transglutaminase has previously been detected on both the platelet surface and in platelet lysates, 6, 20 and factor XIIIA and tissue transglutaminase have similar substrate specificities. 21 In the absence of factor XIIIA, platelet levels of tissue transglutaminase may be sufficient to support coated platelet formation. This possibility could perhaps be tested using tissue transglutaminase deficient mice. 22 Another possible reason for the lack of an effect of FXIIIA is that coated platelet formation may occur through a mechanism that does not require transglutaminase-mediated conjugation of serotonin to platelet proteins. Alternatively, species-related differences in the mechanisms of coated platelet formation between humans and mice may explain these results.
In summary, we have characterized the coated platelet phenotype in murine platelets, and demonstrate a close relationship between coated platelet formation and platelet procoagulant activity. The increased thrombin generation on the surface of the coated platelet may be particularly important in facilitating thrombus formation under conditions in which multiple agonists, such as collagen and thrombin, are present. A key advantage of murine models is the ability to examine the mechanistic role of specific 
